Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05069428 · ClinicalTrials.gov registry record · Phase 4
Delirium Reduction With Ramelteon
A Phase 4 study of Delirium, sponsored by Centennial Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 506
- Enrollment target
- 1
- Study location
NCT05069428: Recruiting Phase 4 study of Delirium, sponsored by Centennial Medical Center.
NCT05069428 is a Phase 4 study of Delirium that is actively recruiting participants, run by Centennial Medical Center. The registered enrollment target is 506 participants, below the 879-participant average among 62 other Delirium trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05069428, a Phase 4 study of Delirium, is actively recruiting participants, sponsored by Centennial Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 506 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to identify a medication that might treat and/or prevent delirium in intensive care unit (ICU). Currently, there is no proven medical therapy for prevention or treatment of delirium. Ramelteon is a medication approved for insomnia. We hypothesize that ramelteon may help regulate the day/night cycle and decrease ICU delirium.
Conditions Studied
Interventions
- DRUG Ramelteon 8mg
Study Locations (1)
Tennessee
- Centennial Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2023-03-26 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
What NCT05069428 shows while recruiting
NCT05069428 is an interventional study that assigns participants to a tested intervention. The registered 506 participants enrollment target is mid-sized for trials with a published cap, below the 879-participant average among 62 other Delirium trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Delirium appearing as the primary indexed condition, and to 1 intervention - of which Ramelteon 8mg is the first listed.
NCT05069428 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05069428 about?
NCT05069428 is a clinical study titled "Delirium Reduction With Ramelteon". The overall purpose of this study is to identify a medication that might treat and/or prevent delirium in intensive care unit (ICU). Currently, there is no proven medical therapy for prevention or treatment of delirium. Ramelteon is a medication approved for insomnia. We hypothesize that ramelteon m...
What is the current status of trial NCT05069428?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 506 participants. The study started on 2023-03-26. Estimated completion is 2025-12.
What conditions does trial NCT05069428 study?
This clinical trial studies the following conditions: Delirium.
What interventions are being tested in trial NCT05069428?
The interventions under investigation include: Ramelteon 8mg (DRUG).
Who is sponsoring clinical trial NCT05069428?
This trial is sponsored by Centennial Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05069428 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delirium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05069428's enrollment target sits among peer trials
506 16th of 62 higher than 47 of 62 other Delirium trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Delirium trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
COMPLETED · Phase 4
-
Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?
COMPLETED · Phase 4
-
Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation
RECRUITING · NA
-
VoiceLove Digital Therapy for Delirium in the ICU
RECRUITING · NA
-
Delirium and Neuropsychological Recovery Among Emergency General Surgery Survivors
RECRUITING · NA
-
TaVNS for Delirium
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT06164717 · 507 participants · NA
Behavioral and Neural Characteristics of Adaptive Speech Motor Control
- NCT02115295 · 508 participants · Phase 2
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
- NCT04692675 · 508 participants · NA
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI